Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 4(5): e5133, 2009.
Article in English | MEDLINE | ID: mdl-19415121

ABSTRACT

BACKGROUND: Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib. Experimental evidence suggests that BRCA1 overexpression enhances sensitivity to docetaxel and resistance to cisplatin. RAP80 and Abraxas are interacting proteins that form complexes with BRCA1 and could modulate the effect of BRCA1. In order to further examine the effect of EGFR mutations and BRCA1 mRNA levels on outcome in advanced NSCLC, we performed a prospective non-randomized phase II clinical trial, testing the hypothesis that customized therapy would confer improved outcome over non-customized therapy. In an exploratory analysis, we also examined the effect of RAP80 and Abraxas mRNA levels. METHODOLOGY/PRINCIPAL FINDINGS: We treated 123 metastatic non-squamous cell lung carcinoma patients using a customized approach. RNA and DNA were isolated from microdissected specimens from paraffin-embedded tumor tissue. Patients with EGFR mutations received erlotinib, and those without EGFR mutations received chemotherapy with or without cisplatin based on their BRCA1 mRNA levels: low, cisplatin plus gemcitabine; intermediate, cisplatin plus docetaxel; high, docetaxel alone. An exploratory analysis examined RAP80 and Abraxas expression. Median survival exceeded 28 months for 12 patients with EGFR mutations, and was 11 months for 38 patients with low BRCA1, 9 months for 40 patients with intermediate BRCA1, and 11 months for 33 patients with high BRCA1. Two-year survival was 73.3%, 41.2%, 15.6% and 0%, respectively. Median survival was influenced by RAP80 expression in the three BRCA1 groups. For example, for patients with both low BRCA1 and low RAP80, median survival exceeded 26 months. RAP80 was a significant factor for survival in patients treated according to BRCA1 levels (hazard ratio, 1.3 [95% CI, 1-1.7]; P = 0.05). CONCLUSIONS/SIGNIFICANCE: Chemotherapy customized according to BRCA1 expression levels is associated with excellent median and 2-year survival for some subsets of NSCLC patients , and RAP80 could play a crucial modulating effect on this model of customized chemotherapy. TRIAL REGISTRATION: (ClinicalTrials.gov) NCT00883480.


Subject(s)
BRCA1 Protein/genetics , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carrier Proteins/genetics , ErbB Receptors/genetics , Mutation , Nuclear Proteins/genetics , Pharmacogenetics/methods , Adult , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Cisplatin/administration & dosage , DNA-Binding Proteins , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Docetaxel , Drug Dosage Calculations , Drug Resistance, Neoplasm/genetics , Female , Histone Chaperones , Humans , Male , Middle Aged , RNA, Messenger/analysis , RNA, Neoplasm/analysis , Survival Rate , Taxoids/administration & dosage , Treatment Outcome , Gemcitabine
2.
Cell Res ; 18(8): 823-33, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18607389

ABSTRACT

MicroRNAs (miRNAs) are essential for regulating cell differentiation and maintaining the pluripotent state of stem cells. Although dysregulation of specific miRNAs has been associated with certain types of cancer, to date no evidence has linked miRNA expression in embryonic and tumor tissues. We assessed the expression of mature miRNAs in human embryonic colon tissue, and in colorectal cancer and paired normal colon tissue. Overlapping miRNA expression was detected between embryonic colonic mucosa and colorectal cancer. We have found that the miR-17-92 cluster and its target, E2F1, exhibit a similar pattern of expression in human colon development and colonic carcinogenesis, regulating cell proliferation in both cases. In situ hybridization confirmed the high level of expression of miR-17-5p in the crypt progenitor compartment. We conclude that miRNA pathways play a major role in both embryonic development and neoplastic transformation of the colonic epithelium.


Subject(s)
Carcinoma/genetics , Cell Transformation, Neoplastic/genetics , Colon/embryology , Colorectal Neoplasms/genetics , Gene Expression Regulation, Neoplastic/genetics , MicroRNAs/genetics , Carcinoma/metabolism , Carcinoma/physiopathology , Cell Differentiation/genetics , Cell Proliferation , Cell Transformation, Neoplastic/metabolism , Colon/cytology , Colon/metabolism , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/physiopathology , E2F1 Transcription Factor/genetics , Humans , Intestinal Mucosa/cytology , Intestinal Mucosa/embryology , Intestinal Mucosa/metabolism , MicroRNAs/biosynthesis , Stem Cells/cytology , Stem Cells/metabolism
3.
Oncology ; 72(5-6): 364-70, 2007.
Article in English | MEDLINE | ID: mdl-18204222

ABSTRACT

BACKGROUND/AIMS: Oxaliplatin damages the DNA, leading to apoptosis. XPA, XPD, ERCC1 and XPG genes are involved in DNA repair, and single nucleotide polymorphisms (SNPs) in these genes can influence the efficacy of oxaliplatin. We examined SNPs in these genes and correlated the results with time to progression (TTP), overall survival and response to oxaliplatin in 42 advanced colorectal cancer patients (CRC) treated with first-line oxaliplatin/fluoropyrimidine. METHODS: DNA was obtained from peripheral blood cells, and the allelic discrimination assay was used to analyze the XPA 5'UTR T/C, XPD Lys751Gln, ERCC1 Lys259Thr and XPG, C/T. RESULTS: Patients with XPG C/C genotype had a longer survival (p = 0.001) and TTP (p = 0.009) than patients with XPG C/T or T/T genotypes, and patients with both XPG C/C and XPA T/C or C/C genotypes had a longer survival (p = 0.0001) and TTP (p = 0.0001) than patients with other genotypes. XPG (CC) combined with XPA (TC/CC) genotypes showed an independent role for TTP (relative risk, RR = 6.38; p = 0.0001) and survival (RR = 34; p = 0.0005). CONCLUSION: Polymorphism in XPG combined with XPA may be an important prognosticator of clinical outcome following oxaliplatin/ fluoropyrimidine chemotherapy. Further studies in larger patient cohorts are warranted to confirm their role in CRC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Colorectal Neoplasms/genetics , DNA-Binding Proteins/genetics , Endonucleases/genetics , Nuclear Proteins/genetics , Transcription Factors/genetics , Xeroderma Pigmentosum Group A Protein/genetics , Xeroderma Pigmentosum Group D Protein/genetics , Adult , Aged , Capecitabine , Colorectal Neoplasms/drug therapy , DNA Repair/genetics , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease Progression , Female , Fluorouracil/administration & dosage , Fluorouracil/analogs & derivatives , Humans , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Polymorphism, Single Nucleotide , Survival Analysis
4.
Cancer Lett ; 233(1): 117-23, 2006 Feb 20.
Article in English | MEDLINE | ID: mdl-16473672

ABSTRACT

Shh is expressed in the early stages of embryogenesis and in the foregut development. Although Shh has been shown to be overexpressed in brain, pancreas, gastric and lung cancers, its role in the development of colorectal cancer has not been examined. We used real-time quantitative PCR to assess Shh mRNA expression levels in tumor and matched normal tissue from 57 colorectal cancer patients and correlated the results with patient clinicopathological characteristics. Shh expression levels were higher in tumor tissue than in normal tissue from the same patient (P=0.00001). Higher levels of Shh expression were associated with early stage disease (P=0.02). Shh overexpression may influence the development of colorectal cancer.


Subject(s)
Colorectal Neoplasms/metabolism , Polymerase Chain Reaction/methods , RNA, Messenger/analysis , Trans-Activators/genetics , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Female , Hedgehog Proteins , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...